Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China to Review IND Filing for CStone/Impact PD-L1/PARP Combo

publication date: Feb 8, 2019

CStone Pharma of Suzhou and Impact Therapeutics of Nanjing announced China's NMPA accepted their IND filing for a cancer therapy that combines CStone's PD-L1 mAb with Impact's PARP inhibitor. In 2018, CStone and Impact agreed to collaborate on global clinical trials for the combination, and the acceptance of the IND filing is the first major regulatory milestone in the collaboration. The companies plan to test the combination as a treatment for advanced solid tumors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

 

China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020

Other Events

CHINA HEALTHCARE SUMMIT 2019

Shanghai, China

November 18-20, 2019